Manila Times Business
Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced preclinical data for REX-8756, an oral, potent and selective STAT6 inhibitor, is being presented at two upcoming scientific congresses. At the European Association of Allergy and Clinical Immunology (EAACI) Congress taking place June 12-15, 2026, in Istanbul, Turkey, a poster will highlight data
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Genesis Wins Best Fixed Income Trading Solution
1h ago
Veyond Metaverse Closes Strategic Investment from Japan-Based Private Investor as Global Commercial Momentum Accelerates Across Its XR Medical Telepresence Platform
1h ago
EXL and Databricks expand collaboration to help enterprises build trusted data foundations for AI
1h ago
BlockchAIn Announces Preliminary Inclusion in Russell Microcap® Index
1h ago